2674036-91-8
Chemical Structure
JAK3/BTK-IN-1
- CAS No.: 2674036-91-8
- Formula:C25H28N8O
- Molecular Weight:456.54
IUPAC Name: (R)-1-(3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
InChIKey: RFHWLYCWPJCJSE-GOSISDBHSA-N
SMILES: C=CC(N1C[C@H](NC2=C3C(NC=C3C4=CC=CC=C4)=NC(NC5=CN(CC)N=C5)=N2)CCC1)=O
Biological Activity: JAK3/BTK-IN-1 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002)[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JAK3/BTK-IN-1 | JAK3/BTK-IN-1 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
